{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-369426","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2026-08-27T10:01:18+00:00","discovered_at":"2026-08-27T10:10:00.383559+00:00","generated_at":"2026-08-27T10:10:07.865855+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cyclerion shareholders approve merger proposals; 1-for-7 reverse split; redomestication fails","bullets":["Shareholders approved Nasdaq issuance, authorized share increase to 700M, reverse split, and 2026 stock plans; redomestication to Cayman failed.","Board set reverse split at 1-for-7, cutting shares from ~4.7M to ~0.7M; fractional shares paid in cash.","Combined company to trade as Korsana Biosciences, Inc. (KRSA) on Nasdaq from Sept 9, 2026, with new CUSIP 23255M303.","Redomestication failure not a condition to close; merger remains pending with closing conditions to be satisfied."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-369426","json":"https://secwatch.observer/filing/0001193125-26-369426.json","markdown":"https://secwatch.observer/filing/0001193125-26-369426.md","text":"https://secwatch.observer/filing/0001193125-26-369426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000119312526369426/0001193125-26-369426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000119312526369426/d264301d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-27T10:10:07.865855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}